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Abstract
Background Early awareness and alert systems have been established in many countries but evidence on their ability to 
accurately prioritize new medicines (for early assessment) is limited.
Objective The purpose of this study was to assess whether the Swedish Early Awareness and Alert System identified and 
prioritized (i.e., produced early assessment reports for) new medicines that would go on to have substantial economic impact.
Methods We adapted a study design commonly used in the assessment of diagnostic test accuracy. The prioritization made 
by the Swedish Early Awareness and Alert System prior to marketing authorization comprised the index test and the national 
drug sales data in the second year post-authorization served as the reference standard. All initial marketing authorization 
applications for medicinal products processed by the European Medicines Agency between 2010 and 2015 (study popula-
tion) were classified using the index test and the reference standard.
Results Two hundred and fifty-three new medicinal products processed by the European Medicines Agency comprised the 
study population. Of these, 71 were prioritized by the Swedish Early Awareness and Alert System and 21 were classified 
as having substantial economic impact. The sensitivity and positive predictive value were 76.2% and 22.5%, respectively. 
Subgroup analyses showed that the accuracy of prioritization, in terms of sensitivity, was 100% for antineoplastic/immu-
nomodulating agents.
Conclusions The Swedish Early Awareness and Alert System identified all new medicines that would go on to have sub-
stantial economic impact and prioritized most of these medicines. Our findings provide reassurance to decision makers who 
rely on the outputs of the Swedish Early Awareness and Alert System to keep informed about new medicines. Moreover, 
this study also provides valuable insights to stakeholders willing to establish or evaluate their own early awareness and alert 
activities and systems.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 8-018-0434-2) contains 
supplementary material, which is available to authorized users.
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Key Points for Decision Makers 
Of the new medicines authorized by the European Medi-
cines Agency from 2010 to 2015, only 10% exceeded 
sales of €4 million (0.1% of total pharmaceutical 
expenditure per year in Sweden) in the second year on 
the market.
Over the first years of work since its establishment in 
2010, the Swedish Early Awareness and Alert System 
identified all new medicines that would go on to have 
substantial economic impact in the first 2 years post-
authorization. For most of these medicines, an early 
assessment report was provided to decision makers 
ahead of the marketing authorization.
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1 Introduction
As already stretched healthcare budgets are put under 
additional pressure with the introduction of new expensive 
medicines [1–4], payers are increasingly seeking greater 
value for their money [5–10]. In addition, timely access to 
new and meaningfully better medicines to improve patient 
outcomes is considered a priority in many countries [11]. 
The early identification of new emerging technologies 
prior to their introduction can enable timely assessments 
to be undertaken and activities established to facilitate 
rational uptake and utilization. However, scrutinizing the 
research and development pipeline to identify medicines 
that may impact healthcare is notoriously difficult and 
requires considerable expertise. Horizon scanning systems 
[also known as early awareness and alert (EAA) systems] 
[12] can provide the necessary support to health technol-
ogy assessment bodies and payers.
Early awareness and alert activities are now recognized 
as a key element in processes for the introduction of new 
medicines [7, 13]. In view of this, the structure, processes, 
outputs, and impact of an EAA system should be regularly 
evaluated and tailored to meet customer needs [14, 15]. It 
is reasonable to assume that an established EAA system 
carries out evaluations of its work as part of improvement 
initiatives. In Sweden, for example, feedback from stake-
holder interviews was used to improve both the process 
and outputs of the Swedish EAA System [16]. However, 
such evaluations are typically internal and of a qualitative 
nature. Furthermore, they may not be readily accessible 
to wider audiences, thereby hampering the opportunity 
to learn from experiences across systems. To date, EAA 
systems with published evaluations include the UK’s 
National Institute for Health Research Horizon Scanning 
Research and Intelligence Centre [17–19], the Austrian 
Horizon Scanning Programme in Oncology [20], and the 
US Agency for Healthcare Research and Quality Health-
care Horizon Scanning System [21].
The Swedish EAA System has been performing EAA 
activities at the national level since 2010. It was estab-
lished to support the long-term planning of the county 
councils and to optimize the readiness of the healthcare 
system to the introduction of new medicines. A detailed 
description of the Swedish EAA System is available else-
where [22]. Both regional and national decision makers 
use the outputs of the system, including early assess-
ment reports produced for prioritized medicines, to keep 
informed and prepared for the introduction of new medi-
cines. The purpose of this study is to assess whether the 
Swedish EAA System identified and prioritized new 
medicines that would go on to have substantial economic 
impact.
2  Methods
2.1  Study Design
We adapted a study design commonly used in the assessment 
of diagnostic test accuracy to compare an index test’s clas-
sification of a target condition with a reference standard’s 
classification [17]. For the purpose of our assessment, the 
prioritization (i.e., selection for early assessment) made by 
the Swedish EAA System comprised the index test and the 
national sales data served as the reference standard. All ini-
tial marketing authorization applications for medicinal prod-
ucts processed by the European Medicines Agency (EMA) 
from 1 January, 2010, to 31 December, 2015 (study popula-
tion) were classified using the index test and the reference 
standard. New indications of already authorized medicinal 
products (extensions of indications) were not included. The 
end date for selecting the study population was chosen to 
provide at least 2 years of follow-up sales data on all medi-
cines following marketing authorization.
2.2  Study Population
To compile the study population, all European Public 
Assessment Reports on medicines, authorized or refused, 
were obtained from EMA website [23]. We also retrieved 
information on all withdrawals of initial marketing authori-
zation applications. All medicines processed from 1 January, 
2010, to 31 December, 2015, were included, regardless if 
they were authorized or refused by EMA, or withdrawn by 
the manufacturer.
We excluded generics, biosimilars, vaccines, as well as 
known active substances with a history of use in clinical 
practice for the applied indication [e.g., asparaginase (Spec-
trila®) for use in acute lymphoblastic leukemia; metformin 
hydrochloride/saxagliptin hydrochloride (Komboglyze®) for 
use in type 2 diabetes mellitus]. Finally, we removed dupli-
cates, such as multiple and informed consent applications. 
The selection process for the study population is presented 
in Fig. 1.
2.3  Index Test
The Swedish EAA System identifies and prioritizes new 
medicines and new indications of already approved medi-
cines that may have an impact on the healthcare system [22]. 
The following criteria are considered in the filtration and 
prioritization steps: the patient population size; burden of 
disease; budget impact; anticipated clinical benefits; level 
of innovation; organizational impact; impact on treatment 
guidelines; safety aspects; level of interest from media 
and patient organizations; anticipated sub-optimal market 
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uptake; and relevance from a legal, ethical and/or political 
aspect.
For a prioritized medicine, an early assessment report, the 
starting point for the national process for managed introduc-
tion and follow-up of new medicines, is produced prior to 
regulatory approval. In addition to early assessment reports, 
the Swedish EAA System produces the following outputs: a 
horizon scanning database of identified new and emerging 
medicines, a list of prioritized medicines (including already 
produced as well as planned early assessment reports), and 
quarterly newsletters. As per agreement with its customers 
(i.e., the New Therapies Council and individual counties), 
the Swedish EAA System seldom produces early assessment 
reports for medicines with existing mechanisms of action for 
indications or for orphan medicines.
The decision to prioritize a new medicine (i.e., to produce 
an early assessment report for a new medicine) comprised 
the index test. We retrieved all early assessment reports pro-
duced from 1 January, 2010, to 31 December, 2015. Reports 
on extensions of indications of already authorized medici-
nal products were excluded (e.g., apixaban [Eliquis®] was 
only included once with no distinction given to its multiple 
indications). Furthermore, we excluded reports for medi-
cines processed by EMA before 1 January, 2010, or after 31 
December, 2015.
2.4  Reference Standard
National drug sales data were used to derive the reference 
standard in our study. The eHealth Agency records complete 
pharmaceutical sales data from all pharmacies, retailers, and 
wholesalers in Sweden [24]. We obtained aggregate monthly 
sales data on hospital sales and dispensed prescription 
medicines in ambulatory care (reimbursed expenditure and 
patient co-payment) from 1 January, 2010, to 31 December, 
2017.
For the main analyses, we calculated sales in the second 
year (i.e., the second 12-month period following the date of 
EMA marketing authorization). We also conducted sensitiv-
ity analyses based on sales in the third year, restricting the 
study population to those medicines with sufficient follow-
up time.
As total annual pharmaceutical sales in Sweden have been 
approximately €4 billion (Euro:Swedish Krona = 9.5, aver-
age 2015–17) for the past few years, we chose 0.1% of that 
value (€4 million in sales per year) as a nominal threshold 
point (cutoff). A new medicine that exceeded this threshold 
in its second year on the market was classified as having sub-
stantial economic impact on the healthcare system (positive 
reference test). In addition, recognizing the arbitrary nature 
of the chosen threshold, we conducted sensitivity analyses 
exploring how varying the cutoff would change our results.
2.5  Statistical Analyses
Baseline characteristics were analyzed using descriptive 
statistics. Categorical data were reported as proportions 
and continuous data as medians with interquartile ranges. 
The accuracy of prioritizations was summarized in a contin-
gency table. Outcome statistics were reported as sensitivity, 
specificity, positive predictive value, and negative predictive 
value with exact binomial 95% confidence intervals. Sen-
sitivity was defined as the proportion of prioritized medi-
cines among all medicines exceeding the sales threshold. 
N = 462 N = 64 N = 104
238 34 33
118 13 20
9 4 10
14 3 3
54 13
43 1
1
71
Early assessment 
reports
Excluded
Extensions of indication
NASs outside of study 
period
Not under EMA's 
centralized procedure
Prioritized 
medicines253
254
Duplicates
EPARs Withdrawn MA 
applications
Excluded
30224
Generics
Biosimilars
Vaccines
KASs for existing 
indication
Duplicates
Study population
Fig. 1  Study population and early assessment report selection flowchart. EMA European Medicines Agency, EPARs European Public Assess-
ment Reports, KASs known active substances, MA marketing authorization, NASs new active substances
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Specificity was defined as the proportion of non-prioritized 
medicines among all medicines below the sales threshold. 
Positive predictive value was defined as the proportion of 
medicines exceeding the sales threshold among all prior-
itized medicines. Negative predictive value was defined as 
the proportion of medicines below the threshold among all 
non-prioritized medicines.
In addition to varying the cutoff for the reference stand-
ard (€2–8 million in annual sales) and timing of sales (sales 
in the third year on the market), we conducted additional 
analyses to restrict the study population to the following 
subgroups: new active substances; orphan medicines; and 
antineoplastic and immunomodulating agents (based on the 
Anatomical Therapeutic Chemical classification).
3  Results
During the study period (2010–2015), we identified 462 
medicinal products that were authorized or refused by 
EMA and an additional 64 medicinal products whose ini-
tial authorization application was withdrawn by the phar-
maceutical company. After applying our exclusion criteria, 
a study population of 253 medicinal products was yielded 
(Fig. 1). Most commonly, in almost three out of four cases, 
the excluded medicines were either generics or known active 
substances intended for use in an already approved indi-
cation. All 253 medicinal products were identified by the 
Swedish EAA System.
During the study period, 104 early assessment reports 
were published (Fig. 1). Of these, 33 reports were excluded 
from our analyses [see Electronic Supplementary Material 
(ESM)]; most frequently for covering extensions of indica-
tions of already authorized medicinal products. This left us 
with 71 prioritized medicines (positive index test).
Table 1 provides a description of the total study popu-
lation and the prioritized medicines. The majority of the 
medicinal products processed by EMA were classified as 
new active substances (86%) and/or were granted marketing 
authorization (83%); among the medicines prioritized by the 
Swedish EAA System these proportions were slightly higher 
at 93% and 90%, respectively. Antineoplastic and immu-
nomodulating agents were the most common group of med-
icines overall (29%) and among the prioritized medicines 
(51%). Early assessment reports were published around 3 
months ahead of the date of marketing authorization [median 
(interquartile range) number of days: 87 (40–187)].
In total, based on analyses of sales data, we classified 
21 new medicinal products as having substantial economic 
impact on the healthcare system (positive reference test). An 
overview of these medicines is provided in Table 2.
A tabular comparison of the prioritizations made by the 
Swedish EAA System and the economic impact is provided 
in Table 3 with corresponding measures of prioritization 
accuracy in Table 4. The Swedish EAA System prioritized 
16 medicinal products for a sensitivity of 76%. The other pri-
oritized medicines (n = 55) were among the 232 medicinal 
products that did not exceed €4 million in sales (correspond-
ing to a specificity of 76%).
Subgroup and sensitivity analyses were generally in line 
with the main analyses. The accuracy of prioritization, in 
terms of sensitivity, was highest for antineoplastic/immu-
nomodulating agents (100%) and new active substances 
(76%). Conversely, the lowest accuracy of prioritization 
was observed when using the lower sales threshold (65%). 
Detailed data are presented in the ESM.
4  Discussion
We found that the Swedish EAA System identified all new 
medicines that would go on to have substantial economic 
impact and prioritized (i.e., produced early assessment 
reports for) most of these medicines. The few non-prior-
itized medicines whose sales exceeded the threshold were 
identified by the system but not selected for an early assess-
ment report because similar medicines had been already 
prioritized and/or marketed earlier (e.g., Sovaldi® had 
already been selected for a report prior to Daklinza® and 
Harvoni®, thus the latter two were not prioritized). Overall, 
these findings indicate that decision makers in Sweden have 
been accurately informed about impending new medicines 
prior to their launch. This awareness allowed, for example, 
for special activities to be set up to facilitate a rational and 
cost-effective introduction of new medicines into clinical 
practice both at the regional [25, 26] and national [27] level. 
Notably, all new medicines comprising the study population 
were identified by the Swedish EAA System. For many of 
the non-prioritized medicines, for which no early assessment 
report was produced, information was summarized and dis-
seminated in other ways (e.g., a list of all identified orphan 
medicines is regularly updated and provided to both regional 
and national stakeholders).
Potential economic impact is however only one of many 
criteria that the Swedish EAA System weighs in the decision 
to prioritize a medicine. For example, factors contributing 
to the prioritization of obesity medicines [e.g., phenter-
mine/topiramate (Qsiva®)] included the patient population 
size, safety aspects, and anticipated media interest. New 
medicines that are seen as innovative methods of treating 
a disease are also prioritized. Bezlotoxumab (Zinplava®) 
as passive immunization against Clostridium difficile tox-
ins, ipilimumab (Yervoy®) for the treatment of advanced 
melanoma, olaparib (Lynparza®) as maintenance treatment 
of platinum-sensitive recurrent BRCA -mutated ovarian can-
cer, and ranibizumab (Lucentis®) for the treatment of visual 
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impairment due to diabetic macular edema were primarily 
prioritized for this reason [16]. The fact that the sales figures 
do not necessarily reflect all prioritization criteria explains 
the relatively low positive predictive value (range: 12–35%), 
i.e., fewer than one in three prioritized medicines went on 
to have a substantial economic impact. The prioritization 
of such medicines may however be equally important. For 
example, new innovative methods to treat diseases may have 
systemic effects on the delivery of healthcare services and 
require preparation ahead of the introduction. Consequently, 
Table 1  Characteristics of 
the study population and the 
medicines prioritized by the 
Swedish Early Awareness and 
Alert (EAA) System
ATC Anatomical Therapeutic Chemical, EMA European Medicines Agency
a Medicinal products authorized or refused by EMA and withdrawals of initial marketing authorization 
applications
b A chemical substance not previously authorized as a medicinal product in the European Union; or an iso-
mer, mixture of isomers, a complex or derivative or salt of a chemical substance previously authorized as a 
medicinal product in the European Union but significantly differing in properties with regard to safety and 
efficacy from that chemical substance previously authorized
Characteristic Study  populationa EAA System pri-
oritized medici-
nal products
n % n %
Medicinal products
 New active  substanceb 217 86 66 93
 Known active substance 36 14 5 7
 Total 253 100 71 100
Marketing authorization status
 Authorized 210 83 64 90
 Refused 14 6 4 6
 Withdrawn 29 11 3 4
Orphan
 Yes 63 25 14 20
 No 190 75 57 80
Year
 2010 21 8 9 13
 2011 37 15 10 14
 2012 34 13 14 20
 2013 53 21 13 18
 2014 52 21 12 17
 2015 56 22 13 18
Therapeutic area based on the ATC classification system
 Alimentary tract and metabolism 31 12 6 8
 Blood and blood-forming organs 20 8 2 3
 Cardiovascular system 15 6 5 7
 Dermatologicals 5 2 1 1
 Genito-urinary system and sex hormones 8 3 1 1
 Systemic hormonal preparations, excluding sex hormones and 
insulins
3 1 0 0
 Anti-infectives for systemic use 27 11 4 6
 Antineoplastic and immunomodulating agents 74 29 36 51
 Musculoskeletal system 7 3 3 4
 Nervous system 21 8 4 6
 Anti-parasitic products, insecticides and repellents 1 0 0 0
 Respiratory system 10 4 5 7
 Sensory organs 6 2 1 1
 Various 16 6 2 3
 ATC missing 9 4 1 1
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given the holistic approach to prioritization employed by 
the Swedish EAA System combined with their efforts to 
improve efficiency (e.g., the Swedish EAA System typically 
does not prioritize medicines with existing mechanisms of 
action for indications or orphan medicines), it is difficult to 
propose revisions to their working methods that would lead 
to improved sensitivity and positive predictive value.
As a byproduct of our analyses, we obtained an overview 
of all new medicines assessed by EMA during the period 
2010–15. We identified 217 new active substances that were 
submitted to EMA during these years. One fourth of these 
were in the oncology/immunology field, and a considerable 
number of medicinal products were also introduced for met-
abolic (diabetes and rare diseases) and infectious diseases. 
Correspondingly, over half of the medicines prioritized by 
the Swedish EAA System were in oncology or immunology, 
which is similar to outputs from other EAA systems [19, 20].
Apart from providing an assessment of how the Swed-
ish EAA System has performed so far in identifying and 
Table 2  Medicinal products with substantial sales in Sweden in the second year on the market
ATC Anatomical Therapeutic Chemical, CLL chronic lymphocytic leukemia, EAA early awareness and alert, EMA European Medicines Agency, 
HIV human immunodeficiency virus, MCL mantle cell lymphoma
a Medicinal products with sales >€4 million in the second year on the market
b Date of early assessment report publication
Medicinal  producta Therapeutic area ATC Common name EMA 
authoriza-
tion date
Prioritization  dateb
Elocta®; Swedish Orphan Biovitrum Hemophilia A B02BD02 Efmoroctocog alfa 2015-11-19 .
Opsumit®; Actelion Hypertension, pulmonary C02KX04 Macitentan 2013-12-20 .
Betmiga®; Astellas Urinary bladder, overactive G04BD12 Mirabegron 2012-12-20 2012-08-24
Triumeq®; ViiV Healthcare HIV infections J05AR13 Abacavir sulfate/dolute-
gravir sodium/lami-
vudine
2014-09-01 .
Daklinza®; Bristol-Myers Squibb Hepatitis C, chronic J05AX14 Daclatasvir 2014-08-22 .
Sovaldi®; Gilead Hepatitis C, chronic J05AX15 Sofosbuvir 2014-01-16 2014-01-24
Harvoni®; Gilead Hepatitis C, chronic J05AX65 Ledipasvir/sofosbuvir 2014-11-17 .
Yervoy®; Bristol-Myers Squibb Melanoma L01XC11 Ipilimumab 2011-07-13 2010-08-19
Opdivo®; Bristol-Myers Squibb Melanoma L01XC17 Nivolumab 2015-06-19 2015-05-06
Keytruda®; Merck Sharp & Dohme Melanoma L01XC18 Pembrolizumab 2015-07-17 2015-01-21
Zelboraf®; Roche Melanoma L01XE15 Vemurafenib 2012-02-17 2012-02-02
Imbruvica®; Janssen-Cilag MCL; CLL L01XE27 Ibrutinib 2014-10-21 2014-08-28
Kyprolis®; Amgen Multiple myeloma L01XX45 Carfilzomib 2015-11-19 2015-10-07
Xtandi®; Astellas Prostatic neoplasms L02BB04 Enzalutamide 2013-06-21 2013-01-29
Zytiga®; Janssen-Cilag Prostatic neoplasms L02BX03 Abiraterone 2011-09-05 2011-10-18
Gilenya®; Novartis Multiple sclerosis L04AA27 Fingolimod 2011-03-17 2010-12-22
Otezla®; Celgene Arthritis, psoriatic; psoriasis L04AA32 Apremilast 2015-01-15 2014-12-09
Entyvio®; Takeda Colitis, ulcerative; Crohn’s 
disease
L04AA33 Vedolizumab 2014-05-22 2014-02-20
Cosentyx®; Novartis Psoriasis L04AC10 Secukinumab 2015-01-15 2014-12-09
Tecfidera®; Biogen Multiple sclerosis N07XX09 Dimethyl fumarate 2014-01-30 2013-02-15
Eylea®; Bayer Wet macular degeneration S01LA05 Aflibercept 2012-11-22 2012-05-18
Table 3  Tabulation by prioritization made by the Swedish  Early 
Awareness and Alert (EAA) System and the economic impact
EAA System prioritization Economic impact
> €4 million ≤ €4 million Total
Prioritized 16 55 71
Not prioritized 5 177 182
Total 21 232 253
Table 4  Measures of 
prioritization accuracy
CI confidence interval, NPV 
negative predictive value, PPV 
positive predictive value
Measure % 95% CI
Sensitivity 76.2 52.8–91.8
Specificity 76.3 70.3–81.6
PPV 22.5 13.5–34.0
NPV 97.3 93.7–99.1
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prioritizing new medicines that would have substantial eco-
nomic impact, this study also contributes to the scarce lit-
erature on the evaluation of EAA activities and systems. As 
outlined in the EuroSCAN methods toolkit, evaluation is an 
important element of an established EAA system [14]. How-
ever, few reports on such evaluations have been published to 
date [15, 17–21, 28]. This could possibly be explained by a 
lack of scientific interest and involvement, but also by meth-
odological challenges, including the definition of a reference 
standard to be used for comparisons. The ideal reference 
standard should be able to reflect the prioritization criteria 
used by an EAA system but it may not be feasible to obtain 
a single measure that captures the criteria in their entirety 
(e.g., the Swedish EAA System’s prioritization criteria range 
from “potential to affect treatment costs” to “legally, ethi-
cally, or politically interesting”).
In addition to sales data, we also considered using other 
variables, including the size of the patient population, 
health technology assessment recommendation, and level 
of innovation. However, a reliable estimation of the size of 
the patient population proved to be difficult primarily owing 
to a lack of data on patient counts, particularly for narrow 
indications. Results of health technology assessments are 
only available for medicines that are included in the phar-
maceutical benefits scheme, but many of those prioritized 
are intended for hospital use only for which, during the 
study period, no national appraisal was made. Finally, we 
also explored approaches to measure the level of innovation 
but found no universally accepted standard that could be 
used in our study.
Using sales data as a reference standard appears to capture 
both directly and indirectly some of the prioritization criteria 
used, including the size of the patient population, the poten-
tial to clinically improve patient outcomes, and the potential 
to affect treatment costs. In addition, sales objectively reflect 
which new medicines are actually adopted in clinical prac-
tice. However, we encountered a number of limitations with 
using sales data as a reference standard. We acknowledge that 
our choice of the timing of sales (i.e., second and third year) 
and the cutoff value is a pragmatic approach to operational-
ize our analyses.
Measuring sales early in the product life cycle may under-
estimate the number of impactful medicines. Reasons for 
this include medicines with slower uptake and medicines 
initially marketed in narrower indications (e.g., non-vita-
min K antagonist oral anticoagulants). We believe, however, 
that early sales are well suited to capture medicines with a 
strong immediate impact that warrant preparedness by the 
healthcare system. The prioritization accuracy was also sen-
sitive to the cutoff values used in our analyses. In the main 
analyses, we used a pre-specified threshold of approximately 
0.1% of yearly total pharmaceutical sales. While this may 
not seem like a high level, in absolute terms the impact can 
be substantial, especially for specialist medicines used in a 
limited number of hospitals. Moreover, the aggregate nature 
of sales data does not allow us to attribute sales to a given 
indication for medicinal products that are used in multiple 
indications.
We also excluded all new vaccines from our analyses as 
no complete sales data were available because of separate 
distribution chains. While no vaccines were prioritized dur-
ing the study period, more recently, in 2017, the Swedish 
EAA System prioritized the herpes zoster vaccine Shingrix® 
[29]. Recent progress in vaccine research and development 
may translate into an increase in breakthrough therapies [30] 
that warrants the inclusion of vaccines in future evaluations.
Finally, there is a possibility that an early assessment 
report could have influenced sales as the two measures are 
not independent (e.g., taking into account the information 
provided by the Swedish EAA System, the New Therapies 
Council or individual counties may have recommended 
not to use a given medicine). Analyses of  information on 
positive and negative recommendations could have been a 
possible way to address this; however, national-level recom-
mendations were not provided until recently and, moreover, 
it was not possible to systematically collect data on all deci-
sions taken at a county level.
This study was carried out as an independent evaluation of 
the Swedish EAA System. While all authors have knowledge 
of this particular EAA system and the role of EAA activities 
in the process of introduction of new medicines in general, 
none of the authors has been involved in decision making on 
which medicines to prioritize. Furthermore, our study is the 
first evaluation of an EAA system to use sales data as a refer-
ence standard to define which new medicines impacted the 
healthcare system. Despite the aforementioned limitations of 
such a one-dimensional measure, we believe it is nonetheless 
of value to explore its utility and share the results of this study 
with stakeholders both in Sweden and internationally.
5  Conclusions
To summarize, our findings provide reassurance to decision 
makers who rely on the outputs of the Swedish EAA System. 
Moreover, this study also contributes to the scarce literature 
on evaluations of EAA activities and systems and thus pro-
vides valuable insights to stakeholders willing to establish 
or evaluate their own EAA activities.
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